Search Results

Filter
  • 1-10 of  165 results for ""Antineoplastic Agents, Immunological""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

[Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice?]

  • Authors : Chillari F; Dipartimento di Scienze biomediche e odontoiatriche e delle immagini morfologiche e funzionali, Università di Messina.; Parisi S

Subjects: Cetuximab*/Cetuximab*/Cetuximab*/administration & dosage ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/radiotherapy ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/pathology

  • Source: Recenti progressi in medicina [Recenti Prog Med] 2024 May; Vol. 115 (5), pp. 1e-6e.Publisher: Il Pensiero Scientifico Editore Country of Publication: Italy NLM ID: 0401271 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; Disease Progression* ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/drug therapy

  • Source: Anti-cancer drugs [Anticancer Drugs] 2024 Oct 01; Vol. 35 (9), pp. 875-877. Date of Electronic Publication: 2024 Jun 28.Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

CD47-SIRPα Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells.

  • Authors : Li B; State Key Laboratory of Oral Disease & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.; Department of Operative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Subjects: CD47 Antigen*/CD47 Antigen*/CD47 Antigen*/antagonists & inhibitors ; CD47 Antigen*/CD47 Antigen*/CD47 Antigen*/metabolism ; Cetuximab*/Cetuximab*/Cetuximab*/pharmacology

  • Source: Cancer research [Cancer Res] 2024 Oct 01; Vol. 84 (19), pp. 3189-3206.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium:

Record details

×
Academic Journal

The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.

  • Authors : Vasiliadou I; Guy's and St. Thomas NHS Foundation Trust, London, UK.; King's College London, London, UK.

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/drug therapy

  • Source: International journal of cancer [Int J Cancer] 2024 Sep 01; Vol. 155 (5), pp. 883-893. Date of Electronic Publication: 2024 Apr 29.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.

  • Authors : Dong S; Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.; Zhao M

Subjects: Killer Cells, Natural*/Killer Cells, Natural*/Killer Cells, Natural*/immunology ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/immunology ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/therapy

  • Source: Frontiers in immunology [Front Immunol] 2024 Aug 21; Vol. 15, pp. 1442673. Date of Electronic Publication: 2024 Aug 21 (Print Publication: 2024).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.

  • Authors : Tsujikawa T; Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, United States.

Subjects: Tumor Microenvironment*/Tumor Microenvironment*/Tumor Microenvironment*/immunology ; Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; Nivolumab*/Nivolumab*/Nivolumab*/adverse effects

  • Source: Frontiers in immunology [Front Immunol] 2024 Jul 29; Vol. 15, pp. 1390873. Date of Electronic Publication: 2024 Jul 29 (Print Publication: 2024).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.

  • Authors : Saba NF; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia.

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; Nivolumab*/Nivolumab*/Nivolumab*/adverse effects ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/radiotherapy

  • Source: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 896-904.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

  • Authors : Hagiwara K; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.; Matsuki T

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/drug therapy ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/blood

  • Source: Anticancer research [Anticancer Res] 2024 Sep; Vol. 44 (9), pp. 4057-4072.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial.

  • Authors : Janopaul-Naylor JR; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Boe L

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; Radiosurgery*/Radiosurgery*/Radiosurgery*/methods ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/pathology

  • Source: Head & neck [Head Neck] 2024 Sep; Vol. 46 (9), pp. 2292-2300. Date of Electronic Publication: 2024 May 24.Publisher: John Wiley And Sons Country of Publication: United States NLM ID: 8902541 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.

  • Authors : Sato R; Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.; Komatsuda H

Subjects: Nivolumab*/Nivolumab*/Nivolumab*/therapeutic use ; B7-H1 Antigen*/B7-H1 Antigen*/B7-H1 Antigen*/metabolism ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/drug therapy

  • Source: Head & neck [Head Neck] 2024 Sep; Vol. 46 (9), pp. 2233-2243. Date of Electronic Publication: 2024 Apr 26.Publisher: John Wiley And Sons Country of Publication: United States NLM ID: 8902541 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  165 results for ""Antineoplastic Agents, Immunological""